VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a "sell" rating on the stock.

A number of other analysts also recently issued reports on VNRX. Benchmark reiterated a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reiterated a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research report on Tuesday, December 10th.

VolitionRx Stock Up 16.3 %

Shares of NYSE:VNRX traded up $0.09 during midday trading on Friday, reaching $0.68. 419,173 shares of the company traded hands, compared to its average volume of 196,770. The firm's fifty day moving average price is $0.67 and its two-hundred day moving average price is $0.66. The firm has a market capitalization of $62.63 million, a price-to-earnings ratio of -1.88 and a beta of 1.17. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Buying and Selling

In related news, Director Guy Archibald Innes purchased 174,764 shares of the firm's stock in a transaction on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the purchase, the director now directly owns 617,085 shares of the company's stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Cameron John Reynolds bought 139,811 shares of the business's stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company's stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock worth $204,212 in the last quarter. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company's stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.09% of the company's stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.